Portfolio company
Kesmalea Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This drug discovery company develops oral, central nervous system penetrant protein degraders to treat oncology and neurological diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cyclera Therapeutics
This company develops catalytic protein degradation therapeutics to treat neuropsychiatric, neurodegenerative and cancer disorders for patients with central nervous system diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Enodia
This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.
Plexium
This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.
Kymera Therapeutics
This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.
Sibylla Biotech
This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.
Ligature Therapeutics
This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.